List view / Grid view

Phenylketonuria (PKU)

 

article

New tRNA tech aims to rewrite rare disease treatment

9 June 2025 | By

Alltrna is redefining the future of rare disease treatment with engineered tRNA therapeutics that target genetic mutations - not just individual diseases. CEO Michelle Werner shares how this bold, mutation-driven approach could unlock universal treatments for thousands of patients long overlooked by traditional medicine.

article

Advancing novel biotherapeutics based on synthetic biology

22 September 2022 | By

Researchers at Synlogic are clearing the path for a new class of medicine – biotherapeutics based on synthetic biology, called synthetic biotics, which are created by programming or engineering bacteria to metabolise or secrete well-validated targets of disease pathophysiology. In this article, Dr Caroline Kurtz, Chief Development Officer at Synlogic, discusses how synthetic…